Effect of streptomycin on the active force of bioengineered heart muscle in response to controlled stretch

被引:11
作者
Birla, R. K. [1 ]
Huang, Y. C. [2 ]
Dennis, R. G. [3 ]
机构
[1] Univ Michigan, Sect Cardiac Surg, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[3] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27514 USA
关键词
cardiac tissue engineering; active force; cell culture; 3-dimensional constructs; bioreactor; streptomycin;
D O I
10.1007/s11626-008-9114-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In this study, we describe a bioreactor system to deliver controlled stretch protocols to bioengineered heart muscle (BEHMs) and test the system when streptomycin (an aminoglycoside antibiotic, which blocks stretch-activated channels) is either added to or excluded from the culture medium. Streptomycin is a very commonly used component of cell culture antibiotic-antimycotic media additives, so its effects on muscle development and functional response to mechanical signals in vitro is worthy of investigation. Our hypothesis is that BEHMs will not adapt to the applied mechanical stretch protocol when streptomycin is present in the culture medium, but will do so when streptomycin is excluded. Bioengineered heart muscles were formed by culturing primary neonatal cardiac myocytes in a fibrin gel using a method previously developed in our laboratory. A custom bioreactor system was designed using SolidWorks and structural components manufactured using fusion deposition modeling. We utilized a stretch protocol of 1 Hz, 10% strain for 7 d. BEHMs were stretched in the presence and absence of streptomycin. As controls, BEHMs were maintained in a cell culture incubator with and without streptomycin. The contractile properties of all BEHMs were evaluated to determine the active force. We were able to demonstrate compatibility of the bioreactor system with BEHMs and were able to stretch 58 constructs with zero incidence of failure. When the BEHMs were stretched in the absence of streptomycin, the active force increased from a mean value of 51.7 +/- 5.6 (N=10) to 102.4 +/- 16.3 mu N (N=10), with p < 0.05. However, BEHMs that were stretched in the presence of streptomycin did not show any significant increase in active force generation. The average active force of BEHMs increased from a mean value of 57.6 +/- 10.2 (N=10) to 91.4 +/- 19.8 mu N (N=10) when stretched in the presence of streptomycin. In this study, we demonstrate compatibility of the a bioreactor system with BEHMs, stability of the BEHMs in response to stretch protocols, and significant functional improvement in response to controlled stretch only when streptomycin is excluded from the culture medium, supporting our hypothesis.
引用
收藏
页码:253 / 260
页数:8
相关论文
共 35 条
[1]  
AKHYARI P, 2002, CIRCULATION S1, P42
[2]  
Baar K, 2004, FASEB J, V18, P275, DOI 10.1096/fj.04-2034fje
[3]   Development of a novel bioreactor for the mechanical loading of tissue-engineered heart muscle [J].
Birla, R. K. ;
Huang, Y. C. ;
Dennis, R. G. .
TISSUE ENGINEERING, 2007, 13 (09) :2239-2248
[4]   In vivo conditioning of tissue-engineered heart muscle improves contractile performance [J].
Birla, RK ;
Borschel, GH ;
Dennis, RG .
ARTIFICIAL ORGANS, 2005, 29 (11) :866-875
[5]   Myocardial engineering in vivo:: Formation and characterization of contractile, vascularized three-dimensional cardiac tissue [J].
Birla, RK ;
Borschel, GH ;
Dennis, RG ;
Brown, DL .
TISSUE ENGINEERING, 2005, 11 (5-6) :803-813
[6]   Design and fabrication of heart muscle using scaffold-based tissue engineering [J].
Blan, Nicole R. ;
Birla, Ravi K. .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2008, 86A (01) :195-208
[7]   Rapamycin inhibits alpha(1)-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes - Evidence for involvement of p70 S6 kinase [J].
Boluyt, MO ;
Zheng, JS ;
Younes, A ;
Long, XL ;
ONeill, L ;
Silverman, H ;
Lakatta, EG ;
Crow, MT .
CIRCULATION RESEARCH, 1997, 81 (02) :176-186
[8]  
Carrier RL, 1999, BIOTECHNOL BIOENG, V64, P580, DOI 10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO
[9]  
2-X
[10]  
Chapekar MS, 2000, J BIOMED MATER RES, V53, P617, DOI 10.1002/1097-4636(2000)53:6<617::AID-JBM1>3.3.CO